Literature DB >> 15701205

Focus on levomepromazine.

Ben Green1, Tor Pettit, Lesley Faith, Kristof Seaton.   

Abstract

This is a review of the uses of levomepromazine in psychiatry, based upon MEDLINE, PSYCLIT and EMBASE literature searches. The main indications for this drug in psychiatry are schizophrenia and schizoaffective disorder. Levomepromazine's sedative properties particularly fit it to use in psychiatric intensive care. There is also some evidence to suggest it has efficacy in drug-resistant psychosis, although this property of the drug does require further research. In other areas of medicine levomepromazine has been used in: alleviating bronchoconstriction; as a preoperative sedative; in terminal pain control and postoperative analgesia; and in the control of nausea. Some antimycobacterial properties have been recorded. The drug should not be prescribed to patients at high risk of accidental or suicidal overdose.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15701205     DOI: 10.1185/030079904X12708

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  4 in total

1.  Theoretical study on the metabolic mechanisms of levmepromazine by cytochrome P450.

Authors:  Yongting Wang; Qiu Chen; Zhiyu Xue; Yan Zhang; Zeqin Chen; Ying Xue
Journal:  J Mol Model       Date:  2016-09-13       Impact factor: 1.810

2.  Additional use of methotrimeprazine for treating refractory agitation in pediatric patients.

Authors:  Sanne van der Zwaan; Roos J Blankespoor; Anton M H Wolters; Caroline Creten; Piet L J M Leroy; Jan N M Schieveld
Journal:  Intensive Care Med       Date:  2011-11-23       Impact factor: 17.440

3.  Assessing short-term risk of ischemic stroke in relation to all prescribed medications.

Authors:  Imre Janszky; Ioannis Vardaxis; Bo Henry Lindqvist; Jens Wilhelm Horn; Ben Michael Brumpton; Linn Beate Strand; Inger Johanne Bakken; Ingvild Vatten Alsnes; Pål Richard Romundstad; Rickard Ljung; Kenneth Jay Mukamal; Abhijit Sen
Journal:  Sci Rep       Date:  2021-11-04       Impact factor: 4.379

4.  A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia.

Authors:  Hidenobu Suzuki; Keishi Gen
Journal:  Neuropsychiatr Dis Treat       Date:  2013-08-28       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.